JMS declares consultant honoraria from 89bio, Alentis, Alexion, Altimmune, AstraZeneca, Bionorica, Boehringer Ingelheim, Gilead Sciences, GSK, Inventiva Pharma, Ipsen, Lilly, Madrigal Pharmaceuticals, MSD, Northsea Therapeutics, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, and Siemens Healthineers; speaker honoraria from AbbVie, Academic Medical Education (AME), Boehringer Ingelheim, Echosens, Forum für Medizinische Fortbildung (FOMF), Gilead Sciences, Madrigal Pharmaceuticals MedicalTribune, MedPublico GmbH, MedScape, and Novo Nordisk; and stockholder options in AGED Diagnostics and Hepta Bio. HG declares research grants from AbbVie, ADS AIPHIA Development Services AG Intercept, ARLA Food for Health, and Intercept; declares consulting fees from Ipsen, NOVO, and Pfizer; is a lecturer for AstraZeneca and Eisai; and is on the Data Monitoring Committee of CAMURUS AB. IK, SL, MTL, and SBN are employees and stakeholders of Novo Nordisk A/S. AJS has stockholder options in Durect, Exhalenz, Genfit, Inversago, Rivus, and Tiziana; has served as a consultant to 89bio, Akero, Aligos, Alnylam, Altimmune, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gilead, Hanmi, Histoindex, Intercept, Madrigal Pharmaceuticals, Merck, Myovant, Northsea, Novo Nordisk, Path AI, Pfizer, Poxel, Promed, Regeneron, Salix, Surrozen, Takeda, and Zydus; his institution has received grants from Boehringer Ingelheim, Echosens, Eli Lilly, Gilead, Hanmi, Intercept, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Salix, and Takeda; and he receives royalties from Elsevier and Wolter Kluwers. MJD has acted as consultant, advisory board member, and speaker for Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; an advisory board member and speaker for AstraZeneca; an advisory board member for Carmot, Pfizer, Roche, ShouTi Pharma, and Zealand; and a speaker for Amgen and Sanofi. MJD has received grants as an investigator in support of investigator-initiated trials from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, and Sanofi-Aventis. Please refer to the accompanying ICMJE disclosure forms for further details.
PubMed
